Sun Pharma agrees to supply at MFN pricing to U.S. medicaid programmes
Sun Pharmaceutical Industries has agreed to provide Most Favoured Nation (MFN) pricing for its products to U.S. Medicaid programs. This move is part of a broader U.S. government initiative to lower prescription drug costs for American citizens.
Why it matters
This agreement highlights the ongoing pressure on pharmaceutical companies to reduce drug prices in the U.S. market through international price benchmarking.
Sun Pharmaceutical Industries will extend Most Favoured Nation (MFN) pricing to state medicaid programmes of the U.S. It has also committed to MFN pricing for future innovative medicine launches.
The announcement followed a White House ceremony on August 31, in which the U.S. government signed agreements with nine pharmaceutical companies, including Sun Pharma, aimed at improving access to affordable medicines for millions of Americans.
Sun Pharma said the agreement recognises its investment in the U.S. market by delaying Section 232 tariffs on innovative pharmaceutical products for over two years. Further terms of the agreements remain confidential, the company said.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in